title: Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of fusaric acid and paclitaxel or carboplatin.
abstract: Combination of a single dose of paclitaxel with three different dosages of FA resulted in significant (P<0.001) reductions in cell number from controls, paclitaxel alone, and FA treatments alone at four different time points. Combination of a single dose of carboplatin with three different dosages of FA resulted in significant (P<0.001) reductions in cell number from controls and carboplatin treatment alone at 72 and 96 h. Our data suggest that these combinations may provide an enhanced anti-tumor effect with respect to HNSCC. Since, FA can be administered orally, this regimen may introduce a paradigm change in chemotherapy for HNSCC.
authors.affiliation: Department of Neural and Behavioral Sciences, Pennsylvania State University College of Medicine, Hershey, PA, USA.
authors.forename: Jeffrey R
authors.initials: JR
authors.lastname: Jaglowski
authors.forename: Brendan C
authors.initials: BC
authors.lastname: Stack
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology; D016190:Carboplatin / Q000494:pharmacology*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000473:pathology; D049109:Cell Proliferation / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005669:Fusaric Acid / Q000494:pharmacology*; D006131:Growth Inhibitors / Q000494:pharmacology*; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D008297:Male; D009062:Mouth Neoplasms / Q000188:drug therapy / Q000473:pathology; D019384:Nucleic Acid Synthesis Inhibitors / Q000494:pharmacology; D017239:Paclitaxel / Q000494:pharmacology*; D013997:Time Factors; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D006131:Growth Inhibitors; D019384:Nucleic Acid Synthesis Inhibitors; D016190:Carboplatin; D005669:Fusaric Acid; D017239:Paclitaxel